Downstream processing for influenza vaccines and candidates: An update

Area of Science:

• Biotechnology and Pharmaceutical Sciences
• Vaccine Development and Manufacturing
• Process Engineering

Background:

• Influenza outbreaks pose significant global health and economic threats, necessitating improved vaccine strategies.
• Current influenza vaccines face limitations in availability and effectiveness against diverse strains, including pandemic threats.
• Novel vaccine platforms (e.g., inactivated, live-attenuated, virus-like particles, recombinant antigens) offer enhanced protection but present new manufacturing challenges.

Purpose of the Study:

• To review recent advancements in downstream processing (DSP) strategies for various novel influenza vaccine formats.
• To highlight improvements in unit operations crucial for efficient and high-quality vaccine production.
• To discuss the impact of new vaccine designs and production platforms on DSP.

Main Methods:

• Comprehensive review of state-of-the-art unit operations in DSP for influenza vaccines, from harvest to formulation.
• Analysis of innovations in stationary phase design, 3D printing, and continuous processing (e.g., continuous chromatography).
• Evaluation of how production platforms and vaccine designs influence DSP requirements.

Main Results:

• Significant progress has been made in optimizing unit operations for enhanced DSP efficiency in novel influenza vaccine manufacturing.
• New technologies like advanced chromatography and continuous processing are crucial for meeting demands for faster development and improved quality.
• DSP strategies are being adapted to accommodate the unique biophysical properties of diverse vaccine candidates.

Conclusions:

• Optimized DSP is critical for the timely and effective production of next-generation influenza vaccines, including universal and pandemic-ready formulations.
• Continuous processing and innovative unit operations are key to addressing the evolving challenges in vaccine manufacturing.
• The integration of upstream and downstream advancements is essential for robust and scalable influenza vaccine production.